Abstract
Pediatric patients with immune-mediated diseases on immunosuppressants have low risk of severe COVID-19 and no increase in flare rate after SARS CoV-2 exposure
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have